Notes:

1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 15.11.2010

2 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end

3 The company has on 28th July ,2010 enterred into a Business Transfer Agreement with Kores(India) Limited for sale and transfer of its Active Pharmaceutical Ingredients (API) business toghether with its Manufacturing facilities located at plot Nos A-88 and D-10,MIDC, Kurkumbh, Pune , Maharashtra.

4 The Company has issued USD 50 Million zero coupon Foreighn Currency Convertible Bonds in November-2005. No Provision have been made during the year for foreign exchange difference account and for Yield to maturity(YTM) in case of Foreign Currency Convertible Bond.The bonds have become due for redemption on 09th November,2010 and were not redeemed. The Company is in constructive conversations with bond holders for the restructuring of the bonds

5 The Company is primarily engaged in a single segment business of Manufacturing & Marketing of Pharmaceutical Formulations and Active Pharmaceuticals Ingredients and is managed as one entity, for its various activities and is governed by similar set of risk and returns.

6 There were no pending investor complaints at the beginning and end of the Quarter. The Company has not received any investor complaint during the Quarter.

7 Previous year's figures have been re-grouped/re-classified, whereever necessary, so as to make them comparable with the current year's figures.

8 Statement of Assets and Liabilities.

(Rs. In Lakhs)

Particulars	YEAR ENDED 30.09.2010 UNAUDITED	YEAR ENDED 30.09.2009 UNAUDITED
SHAREHOLDERS FUND:		
(a) Capital	5,028.07	5,028.06
(b) Reserve and Surplus	6,031.23	6,052.32
LOAN FUNDS	31,114.18	32,997.17
FIXED ASSETS	22,303.30	28,708.11
INVESTMENTS	6,761.64	6,761.64
CURRENT ASSETS , LOANS AND ADVANCES		
(A) Inventories	4,055.71	9,173.20
(B) Sundry Debtors	7,171.16	5,914.28
(c) Cash and Bank balance	2,387.08	2,253.92
(d) Other current assets		
(e) Loans and Advances	2,730.80	1,989.48
Less: Current Liabilities and Provisions		
(a) Liabilities and provision	3,386.25	3,807.05
Deferred Tax Assets/(Liability) (Net)	(1,150.00)	(1,124.81)
MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)	20.52	47.95
PROFIT AND LOSS ACCOUNT	(1,279.53)	5,839.17

For MARKSANS PHARMA LIMITED

MARK SALDANHA

Place Mumbai
Date 15 11 2010